Trial watch: Peptide-based vaccines in anticancer therapy

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Peptide-based anticancer vaccines target tumor-associated antigens (TAAs) to stimulate immune responses.
• Clinical applications have shown limited therapeutic efficacy due to tumor-intrinsic antigenicity reduction and immunosuppressive tumor microenvironments.
• Current research focuses on overcoming these limitations to enhance vaccine effectiveness.

Purpose of the Study:

• To review recent preclinical and clinical advancements in peptide-based vaccines for cancer therapy.
• To highlight strategies employed to enhance the efficacy of peptide vaccines.
• To discuss the potential of personalized peptide vaccination (PPV) in cancer treatment.

Main Methods:

• Review of preclinical and clinical studies on peptide-based anticancer vaccines.
• Analysis of strategies including immunostimulatory adjuvants, combination therapies with cytotoxic agents, and immune checkpoint blockade.
• Examination of personalized peptide vaccination (PPV) approaches.

Main Results:

• Limited therapeutic activity of early peptide vaccines due to tumor evasion mechanisms.
• Development of strategies to enhance antigenicity and overcome immunosuppression.
• Emerging promise for personalized peptide vaccination (PPV) and combination therapies.

Conclusions:

• Peptide-based vaccines face challenges but offer a promising avenue for cancer immunotherapy.
• Combination strategies and personalized approaches are key to improving therapeutic outcomes.
• Continued research is vital for optimizing peptide vaccine development and clinical application.